
    
      In this Phase I study, the primary objective is to investigate the safety and tolerability of
      SKI2670 after oral administration in healthy female subjects.

      Secondary objective is to investigate the pharmacokinetics and pharmacodynamics of SKI2670
      after oral administration in healthy female subjects.
    
  